Antiviral therapy for respiratory viral infections in immunocompromised patients

References

• Corti M, Palmero D, Eiguchi K. Respiratory infections in immunocompromised patients. Curr Opin Pulm Med. 2009;15(3):209–217.
   PubMed Web of Science ®Google Scholar
• Englund J, Feuchtinger T, Ljungman P. Viral infections in immunocompromised patients. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S2–S5.
   Google Scholar
• Protheroe RE, Kirkland KE, Pearce RM. The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study. Bone Marrow Transplant. 2012;47:88–94.
   PubMed Web of Science ®Google Scholar
• Gainer SM, Patel SJ, Seethamraju H, et al. Increased mortality of solid organ transplant recipients with H1N1 infection: a single center experience. ClinTransplant. 2012;26:229–237.
   Google Scholar
• Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24:333–343.
   PubMed Web of Science ®Google Scholar
• Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143:455–467.
   PubMed Web of Science ®Google Scholar
• Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193:1619–1625.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1–24.
   PubMedGoogle Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55:2803.
   PubMed Web of Science ®Google Scholar
• Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008 Jan 31;13(5):8026.
   PubMedGoogle Scholar
• Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015;117:27–38.
   PubMed Web of Science ®Google Scholar
• L’Huillier AG, Abed Y, Petty TJ, et al. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. J Infect Dis. 2015;212:1726.
   PubMed Web of Science ®Google Scholar
• Tamura D, DeBiasi RL, Okomo-Adhiambo M, et al. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. J Infect Dis. 2015;212(8):1209–1213.
   PubMed Web of Science ®Google Scholar
• Takashita E, Fujisaki S, Kishida N, et al. Characterization of neuraminidase inhibitor-resistant influenza A (H1N1) pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respir Viruses. 2013;7(6):1390–1399.
   PubMed Web of Science ®Google Scholar
• Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014;14:609.
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Martino R, Ward KN, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56(2):258–266.
   PubMed Web of Science ®Google Scholar
• Hause BM, Collin EA, Liu R, et al. Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family. Mbio. 2014;5(2):e00031-14.
   PubMed Web of Science ®Google Scholar
• A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ. 1980;58(4):585–591.
   PubMed Web of Science ®Google Scholar
• Davlin SL, Blanton L, Kniss K, et al. Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep. 2016;65(22):567–575.
   PubMed Web of Science ®Google Scholar
• Weigt SS, Gregson AL, Deng JC, et al. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32(4):471–493.
   PubMed Web of Science ®Google Scholar
• Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin Infect Dis. 2010;23:365–373.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85(5):278–287.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Guthrie KA, Corey L, et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300–1306.
   PubMed Web of Science ®Google Scholar
• Ljungman P. Respiratory virus infections in stem cell transplant patients: the european experience. Biol Blood Marrow Transplant. 2001;7(Suppl):5S–7S.
   Google Scholar
• Choi SM, Boudreault AA, Xie H, et al. Differences in clinical outcomes after 2009 influenza a/h1n1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011;117:5050–5056.
   PubMed Web of Science ®Google Scholar
• Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol. 2011;1:563–573.
   PubMed Web of Science ®Google Scholar
• Bui M, Whittaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol. 1996;70(12):8391–8401.
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Zuccotti G. Adamantane resistance in influenza A. JAMA. 2006;295:934.
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175.
   PubMed Web of Science ®Google Scholar
• Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep. 2010;59:901.
   PubMedGoogle Scholar
• Interim guidance on infection control measures for 2009 H1N1 influenza in healthcare settings, including protection of healthcare personnel. CDC.Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available from: http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm [cited 2016 Jul 16]
   Google Scholar
• South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013;346:f3039.
   PubMed Web of Science ®Google Scholar
• Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis. 2013;57:1511.
   PubMed Web of Science ®Google Scholar
• CDC. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients—seattle, Washington, 2009. Mmwr. 2009;58:893–896.
   PubMedGoogle Scholar
• Laplante J, St George K. Antiviral resistance in influenza viruses: laboratory testing. Clin Lab Med. 2014;34:387–408.
   PubMed Web of Science ®Google Scholar
• Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193:760.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Awad T, Boivin G, et al. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis. 2011;11:134.
   PubMed Web of Science ®Google Scholar
• Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15(4):552–560.
   PubMed Web of Science ®Google Scholar
• Fluview: 2015-2016 Influenza Season Week 28 ending July 16, 2016. Atlanta, GA: US Department of Health and Human Services, CDC, Atlanta, GA; 2010. Available from: http://www.cdc.gov/flu/weekly. [ cited 2016 Jul 26].
   Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016.
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group Lancet. 2000;355:1845.
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235.
   PubMed Web of Science ®Google Scholar
• Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874.
   PubMed Web of Science ®Google Scholar
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998;352:1877–1881.
   Google Scholar
• A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300mg or 600mg of intravenous zanamivir twice daily compared to 75mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza use [Internet]. GlaxoSmithKline Brentford, United Kingdom. Available from: http://www.gsk-clinicalstudyregister.com/files2/gsk-114373-clinical-study-result-summary.pdf [cited 2016 Sept 16].
   Google Scholar
• Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for IV zanamivir available for compassionate use. European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/02/WC500074124.pdf. [ cited 2016 Jun 28]
   Google Scholar
• Chan-Tack KM, Kim C, Moruf A, et al. Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014). Antivir Ther. 2015;20(5):561–564.
   PubMed Web of Science ®Google Scholar
• MedWatch Safety Alert. Relenza (zanamivir) inhalation powder. United States Food and Drug Administration. Silver Spring, MD. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm ( cited 2016 Jul 26).
   Google Scholar
• FDA approves Rapivab to treat flu infection. United States Food and Drug Administration. Silver Spring, MD. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm ( cited 2016 Jun 23).
   Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568.
   PubMed Web of Science ®Google Scholar
• Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349–361.
   PubMed Web of Science ®Google Scholar
• Renaud C, Pergam SA, Polyak C, et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis. 2010;12(6):513–517.
   PubMed Web of Science ®Google Scholar
• Shetty AK, Ross GA, Pranikoff T, et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant. 2012;16(5):E153–7.
   PubMed Web of Science ®Google Scholar
• Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010 May 1;50(9):1252–1255.
   PubMed Web of Science ®Google Scholar
• Hoffman KB, Demakas A, Erdman CB, et al. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ. 2013;347:f4656.
   Google Scholar
• Sugaya N, Kohno S, Ishibashi T, et al. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother. 2012 Jan;56(1):369–377.
   PubMed Web of Science ®Google Scholar
• Casscells SW, Granger E, Kress AM, et al. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21:79.
   PubMedGoogle Scholar
• Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J. 2008;27:88.
   PubMed Web of Science ®Google Scholar
• Hara K, Tanabe T, Nakano R, et al. Clinical characteristics of children with abnormal behaviors associated with influenza infection. J Jpn Pediatr Soc. 2007;111:38.
   Google Scholar
• Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect. 2003;36:111.
   PubMedGoogle Scholar
• Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J. 2009;28:647.
   PubMed Web of Science ®Google Scholar
• Tanabe T, Hara K, Nakajima M, et al. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev. 2010;32:440.
   PubMed Web of Science ®Google Scholar
• Moss RB, Hansen C, Sanders RL, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012;206(12):1844–1851.
   PubMed Web of Science ®Google Scholar
• Zenilman JM, Fuchs EJ, Hendrix CW, et al. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res. 2015;123:114–119.
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA. 2010;107(2):882–887.
   PubMed Web of Science ®Google Scholar
• Sleeman K, Mishin VP, Deyde VM, et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 2010;54(6):2517–2524.
   PubMed Web of Science ®Google Scholar
• Smee DF, Tarbet EB, Furuta Y, et al. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol. 2013;8(11):1085–1094.
   PubMed Web of Science ®Google Scholar
• Tarbet EB, Vollmer AH, Hurst BL, et al. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Arch Virol. 2014;159(6):1279–1291.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167.
   PubMed Web of Science ®Google Scholar
• Kashiwagi S, Watanabe A, Ikematsu H, et al. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza. Clin Infect Dis. 2016; 63(3):330–337.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg. Daiichi Sankyo Company, Limited, Japan. Available from: http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006497.html. [ cited 2016 Dec7]
   Google Scholar
• Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014;57(15):6668–6678.
   PubMed Web of Science ®Google Scholar
• Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015;59(3):1569–1582.
   PubMed Web of Science ®Google Scholar
• Study of acute uncomplicated seasonal influenza A in adult subjects. Janssen Pharma, Titusville, USA. Available from: https://clinicaltrials.gov/ct2/show/NCT02342249 [ cited 2016 Dec7]
   Google Scholar
• Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103.
   PubMed Web of Science ®Google Scholar
• Belardo G, Cenciarelli O, La Frazia S, et al. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob Agents Chemother. 2015;59(2):1061–1069.
   PubMed Web of Science ®Google Scholar
• Trial to evaluate the efficacy and safety of nitazoxanide in the treatment of acute uncomplicated influenza. Romark Laboratories, Florida, USA. Available from: https://clinicaltrials.gov/ct2/show/NCT02612922 [ cited 2016 Dec 7]
   Google Scholar
• McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016;129:21–38.
   PubMed Web of Science ®Google Scholar
• A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza. AstraZeneca, Gaithersburg, Maryland, USA. Available from: https://clinicaltrials.gov/ct2/show/NCT02603952 [ cited 2016 Dec7.]
   Google Scholar
• Tharakaraman K, Subramanian V, Viswanathan K, et al. A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc Natl Acad Sci USA. 2015;112(35):10890–10895.
   PubMed Web of Science ®Google Scholar
• Wollacott AM, Boni MF, Szretter KJ, et al. Safety and upper respiratory pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks. EBioMedicine. 2016;5:147–155.
   PubMed Web of Science ®Google Scholar
• Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10(5):394–403.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–1759.
   PubMed Web of Science ®Google Scholar
• Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. An immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with respiratory syncytial virus infections. Blood. 2014;123:3263–3268.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Fishman JE, Cleary T, et al. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience. Transpl Infect Dis. 2012;14(1):64–71.
   PubMed Web of Science ®Google Scholar
• Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. 2006;16(1):37–48.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics (AAP), Kimberlin DW, Brady MT, Jackson MA, et al., eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.
   Google Scholar
• Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68:1872–1880.
   PubMed Web of Science ®Google Scholar
• Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117:2755–2763.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Aitken SL, Wolfe CR, et al. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634–636.
   PubMed Web of Science ®Google Scholar
• Gross AE, Bryson ML. Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections: A Systematic Review. Ann Pharmacother. 2015;49(10):1125–1135.
   PubMed Web of Science ®Google Scholar
• Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402–412.
   PubMed Web of Science ®Google Scholar
• Molinos-Quintana A, Perez-De Soto C, Gomez-Rosa M, et al. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic sct recipients. Bone Marrow Transplantation. 2013;48:265–268.
   PubMed Web of Science ®Google Scholar
• Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24(12):2114–2119.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Hirsch RL, Fuentes RJ, et al. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation— a compassionate use experience. Bonemarrow Transplant. 2000;25(2):161–165.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatric (AAP). Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–420.
   PubMed Web of Science ®Google Scholar
• Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant. 2010;16(9):1265–1271.
   PubMed Web of Science ®Google Scholar
• De Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2007;45(8):1019–1024.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, McLaurin KK. The Medicaid cost of palivizumab. J Pediatric Infect Dis Soc. 2015;4(1):83–84.
   PubMedGoogle Scholar
• Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16:393.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751.
   PubMed Web of Science ®Google Scholar
• Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy. 2004;24:932.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson R, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107:8800–8805.
   PubMed Web of Science ®Google Scholar
• Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011;183:531–538.
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–221.
   PubMed Web of Science ®Google Scholar
• Mackman RL, Sangi M, Sperandio D, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015;58:1630–1643.
   Google Scholar
• Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract. ClinicalTrials.gov., U.S. National Institutes of Health, Bethesda, MD. Available from: http://clinicaltrials.gov/show/NCT02254408. cited 2016 Jul 12
   Google Scholar
• Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract. ClinicalTrials.gov., U.S. National Institutes of Health, Bethesda, MD. Available from: http://clinicaltrials.gov/show/NCT02254421. [ cited 2016 Jul 29].
   Google Scholar
• ClinicalTrials.gov. A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers. Available from: http://clinicaltrials.gov/show/NCT01355016. [ cited 2016 Jul 29].
   Google Scholar
• Wang G, Deval J, Hong J, et al. Discovery of 4ʹ-chloromethyl-2ʹ-deoxy-3ʹ,5ʹ-di- O-isobutyryl-2ʹ-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015;58(4):1862–1878.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711–722.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2015;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• RI-001 in immunosuppressed respiratory syncytial virus (RSV) infected patients at risk of lower tract RSV illness. ClinicalTrials.gov., U.S. National Institutes of Health, Bethesda, MD. Available from: http://clinicaltrials.gov/show/NCT00632463. [ cited 2016 Jul 29].
   Google Scholar
• Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125:e35–e51.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research Division of Anti-Viral Products (DAVP) Advisory Committee Briefing Document. U.S. Food and Drug Administration, Silver Spring, MD. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm241510.pdf. [ cited 2016 Sept 16]
   Google Scholar
• Fry AM, Curns AT, Harbour K, et al. Anderson LJ Seasonal trends of human parainfluenza viral infections: united states, 1990-2004. Clin Infect Dis. 2006;43:1016–1022.
   PubMed Web of Science ®Google Scholar
• Shah DP, Shah PK, Azzi JM, et al. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett. 2016 Jan 28;370(2):358–364.
   PubMed Web of Science ®Google Scholar
• Renaud C, Englund JA. Antiviral therapy of respiratory viruses in haematopoietic stem cell transplant recipients. Antivir Ther. 2012;17(1Pt B):175–191.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012;119(12):2738–2745.
   PubMed Web of Science ®Google Scholar
• Park SY, Baek S, Lee SO, et al. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother. 2013;57:983–989.
   PubMed Web of Science ®Google Scholar
• Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther. 2011;16:733–740.
   PubMed Web of Science ®Google Scholar
• Guzmán-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis. 2012;14(4):427–433.
   PubMed Web of Science ®Google Scholar
• Chalkias S, Mackenzie MR, Gay C, et al. DAS 181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis. 2014;16:141–144.
   PubMed Web of Science ®Google Scholar
• Waghmare A, Wagner T, Andrews R, et al. Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children. J Pediatric Infect Dis Soc. 2015;4(2):114–118.
   PubMed Web of Science ®Google Scholar
• Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016;22(5):965–970.
   PubMedGoogle Scholar
• An open label study to examine the effects of das181 administered by dry powder inhaler (DPI) or nebulized formulation in immunocompromised subjects with parainfluenza (PIV) infection. Ansun BioPharma I, San Diego, CA. Available from: https://clinicaltrials.gov/ct2/show/NCT01924793 [ cited 2016 Jun 28]
   Google Scholar
• Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016;22(5):965–970.
   PubMedGoogle Scholar
• Alymova IV, Watanabe M, Boyd KL, et al. Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation. Antivir Ther. 2009;14(7):891–898.
   PubMed Web of Science ®Google Scholar
• Alymova IV, Taylor G, Takimoto T, et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother. 2004;48(5):1495–1502.
   PubMed Web of Science ®Google Scholar
• Jacobs SE, Lamson DM, St George K, et al. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–162.
   PubMed Web of Science ®Google Scholar
• Fendrick AM, Monto AS, Nightengale B, et al. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494.
   PubMed Web of Science ®Google Scholar
• Winther B, Hayden FG, Hendley JO. Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: association with symptomatic illness and effect of season. J Med Virol. 2006;78(5):644–650.
   PubMed Web of Science ®Google Scholar
• Kraft CS, Jacob JT, Sears MH, et al. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–1063.
   PubMed Web of Science ®Google Scholar
• Jacobs SE, Lamson DM, Soave R, et al. Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. J Clin Virol. 2015;71:51–58.
   PubMed Web of Science ®Google Scholar
• Jacobs SE, Soave R, Shore TB, et al. Human rhinovirus infections of the lower respiratory tract in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15(5):474–486.
   PubMed Web of Science ®Google Scholar
• Parody R, Rabella N, Martino R, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol. 2007;82:807–811.
   PubMed Web of Science ®Google Scholar
• Kaiser L, Aubert J-D, Pache J-C, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174(12):1392–1399.
   PubMed Web of Science ®Google Scholar
• Costa C, Bergallo M, Astegiano S, et al. Detection of human rhinoviruses in the lower respiratory tract of lung transplant recipients. Arch Virol. 2011;156(8):1439–1443.
   PubMed Web of Science ®Google Scholar
• Thibaut HJ, De Palma AM, Neyts J. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2012;83(2):185–192.
   PubMed Web of Science ®Google Scholar
• Matz J. Vapendavir significantly improves upper respiratory symptoms of naturally acquired rhinovirus infection in asthmatic adults: results of a phase 2 clinical trial. Eur Respir J. 2013;42:1493.
   Web of Science ®Google Scholar
• Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36(12):1523–1532.
   PubMed Web of Science ®Google Scholar
• Pevear DC, Hayden FG, Demenczuk TM, et al. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005;49(11):4492–4499.
   PubMed Web of Science ®Google Scholar
• Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis. 2002 May;2(5):264.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47(12):3907–3916.
   PubMed Web of Science ®Google Scholar
• Patick AK, Brothers MA, Maldonado F, et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49(6):2267–2275.
   PubMed Web of Science ®Google Scholar
• Djukanović R, Harrison T, Johnston SL, et al. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. Randomized Trialam J Respir Crit Care Med. 2014;190(2):145–154.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen BG, De Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 2001;7:719–724.
   PubMed Web of Science ®Google Scholar
• Agapov E, Sumino KC, Gaudreault-Keener M, et al. Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness. J Infect Dis. 2006;193(3):396–403.
   PubMed Web of Science ®Google Scholar
• Deffrasnes C, Hamelin ME, Prince GA, et al. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother. 2008;52(1):279–287.
   PubMed Web of Science ®Google Scholar
• Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis. 2005;192(6):1061–1065.
   PubMed Web of Science ®Google Scholar
• Shah DP, Shah PK, Azzi JM, et al. Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett. 2016;379(1):100–106.
   PubMed Web of Science ®Google Scholar
• Seo S, Gooley TA, Kuypers JM, et al. Human metapneumovirus infections following hematopoietic cell transplantation: factors associated with disease progression. Clin Infect Dis. 2016;63(2):178–185.
   PubMed Web of Science ®Google Scholar
• Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60(1):51–59.
   PubMed Web of Science ®Google Scholar
• Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50(2):774–777.
   PubMed Web of Science ®Google Scholar
• Kitanovski L, Kopriva S, Pokorn M, et al. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol. 2013;35(7):e311–3.
   PubMed Web of Science ®Google Scholar
• Shachor-Meyouhas Y, Ben-Barak A, Kassis I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. Pediatr Blood Cancer. 2011;57(2):350–351.
   PubMed Web of Science ®Google Scholar
• Shahda S, Carlos WG, Kiel PJ, et al. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011;13(3):324–328.
   PubMed Web of Science ®Google Scholar
• Miller SA, Tollefson S, Crowe JE Jr, et al. Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region. J Virol. 2007;81(1):141–149.
   PubMed Web of Science ®Google Scholar
• Ulbrandt ND, Ji H, Patel NK, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006;80(16):7799–7806.
   PubMed Web of Science ®Google Scholar
• Hamelin ME, Gagnon C, Prince GA, et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res. 2010 Oct;88(1):31–37.
   PubMed Web of Science ®Google Scholar
• Greenberg SB. Update on rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2011;32(4):433–446.
   PubMed Web of Science ®Google Scholar
• Adedeji AO, Severson W, Jonsson C. et al. Novel Inhibitors SARS-Cov Entry Acting by Three Distinct Mechanisms J Virol. 2013;87:8017–8028.
   Google Scholar
• Elshabrawy HA, Coughlin MM, Baker SC, et al. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012;7(11):e50366.
   PubMed Web of Science ®Google Scholar
• Schneider M, Ackermann K, Stuart M, et al. Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virol. 2012;86(18):10112–10122.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhao Z, Zhou D, et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides. 2011;32(7):1518–1525.
   PubMed Web of Science ®Google Scholar